New Partnership Set to Break New Ground in Medical Diagnostics

Revolutionary Partnership in Medical Diagnostics CardiAI, a leading biotechnology company specializing in cutting-edge diagnostic solutions, has announced a collaboration with the Faculty of Engineering and Design at Carleton University. This partnership marks an important milestone in advancing medical diagnostics through the application of Electrolyte-Gated Field-Effect Transistor (EG-FET) biosensor technology. The collaboration between CardiAI and Carleton aims to leverage the potential of EG-FET biosensors to detect critical biomarkers in saliva and whole blood. This joint effort not only promises to revolutionize point-of-care diagnostics, but also lays the groundwork for expanding the technology's applications to a broader range of health conditions. Cardiologist and CardiAI Chief Executive Officer Dr. Anmol S. Kapoor said, "We are excited to embark on this transformative journey with Carleton University," and added "The combination of CardiAI's biotechnology expertise with Carleton's prowess in electronics engineering creates a synergy that holds great promise for the future of medical diagnostics. Together, we are committed not only to addressing current healthcare challenges, but also to developing technology that drives innovation and improves patient outcomes." This strategic partnership takes place at a critical time when the global healthcare landscape is evolving, emphasizing the importance of accessible and efficient medical testing. The innovative EG-FET biosensor technology is poised to play a crucial role in democratizing healthcare by delivering accurate and rapid diagnostic results, particularly for individuals in remote regions with limited access to major hospitals. Dr. Ravi Prakash, Associate Professor in the Department of Electronics at Carleton and Director of Carleton Organic Sensors and Devices Laboratory, said, "This partnership underscores the power of interdisciplinary collaborations in advancing scientific progress." "Our department is excited to contribute to the development of the latest biosensor technology with the potential to redefine point-of-care diagnostics. By leveraging our research capabilities, we aim to create a lasting impact on healthcare accessibility and usher in a new era of medical innovation."

Key Highlights of the Partnership

Cutting-Edge Biosensor Technology: The collaboration focuses on the development and implementation of EG-FET biosensor platforms to detect NT-proBNP and cardiac troponin biomarkers, promising highly sensitive and specific results to enhance medical diagnostic precision. The partnership aims to contribute to the development of new diagnostic solutions for various health conditions, going beyond cardiovascular biomarkers. Global Impact: Joint research and development efforts will not only benefit local communities but will also have global reach. The partnership seeks to improve medical test accessibility through point-of-care diagnostics, positively impacting individuals worldwide and providing timely and accurate healthcare solutions. Integration with BioAro's BioEMR: To maximize the potential of EG-FET biosensor technology, CardiAI and Carleton University will integrate this technology with BioEMR, BioAro's artificial intelligence-enabled Telehealth Platform and Electronic Medical Record (EMR) system. This integration aims to create a seamless healthcare ecosystem by facilitating efficient patient management and diagnostic reporting. Source